Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson's disease in rats.

Bashir, B; Mittal, S; Muthukumar, A; Vishwas, S; Pandey, NK; Gulati, M; Gupta, G; Dhanasekaran, M; Kumar, P; Dureja, H; Veiga, F; Paiva-Santos, AC; Adams, J; Dua, K; Singh, SK

Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson's disease in rats.

Bashir, B Mittal, S Muthukumar, A Vishwas, S Pandey, NK Gulati, M Gupta, G Dhanasekaran, M Kumar, P Dureja, H Veiga, F Paiva-Santos, AC Adams, J Dua, K

Singh, SK

Permalink

Publisher:: Elsevier BV
Publication Type:: Journal Article
Citation:: Eur J Pharmacol, 2023, pp. 176234
Issue Date:: 2023-12-01

Closed Access

	Filename	Description	Size
	Benfotiamine_MPTP induced Parkinson's.pdf	Published version	5.08 MB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Bashir, B
dc.contributor.author	Mittal, S
dc.contributor.author	Muthukumar, A
dc.contributor.author	Vishwas, S
dc.contributor.author	Pandey, NK
dc.contributor.author	Gulati, M
dc.contributor.author	Gupta, G
dc.contributor.author	Dhanasekaran, M
dc.contributor.author	Kumar, P
dc.contributor.author	Dureja, H
dc.contributor.author	Veiga, F
dc.contributor.author	Paiva-Santos, AC
dc.contributor.author	Adams, J
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Singh, SK
dc.date.accessioned	2023-12-07T12:23:51Z
dc.date.available	2023-11-28
dc.date.available	2023-12-07T12:23:51Z
dc.date.issued	2023-12-01
dc.identifier.citation	Eur J Pharmacol, 2023, pp. 176234
dc.identifier.issn	0014-2999
dc.identifier.issn	1879-0712
dc.identifier.uri	http://hdl.handle.net/10453/173769
dc.description.abstract	The study was performed to evaluate the neuroprotective effects of Benfotiamine (BFT) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) in rats. The rats were given daily doses of BFT (100mg/kg, 200mg/kg) through oral administration for 42 days. The rats were given a single bilateral dosage of MPTP (0.1 mg/nostril) intranasally once before the drug treatment to induce PD. On day 42, the animals were subjected to various behavioral paradigms. Post-treatment with BFT for 42 days significantly improved the motor and nonmotor fluctuations of MPTP. The results demonstrated that treatment with BFT ameliorated MPTP-induced disorders in behavior, body balance, and dopamine levels in the mid-brain. Among the post-treated groups, a high dose of BFT was the most effective treatment. Mean values are indicated in ±SEM, n = 5***(p < 0.001) when compared with the vehicle control, n = 5 ### (p < 0.001) when compared with the disease control; (p < 0.001) when compared with the BFT per se; (p < 0.001) when compared with the low dose of BFT; (p < 0.001) when compared with the high dose of BFT. Our finding suggests that BFT contributed to superior antioxidant, and anti-inflammatory and could be a novel therapeutic method for PD management. In conclusion, BFT could be a potential drug candidate for curbing and preventing PD.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier BV
dc.relation.ispartof	Eur J Pharmacol
dc.relation.isbasedon	10.1016/j.ejphar.2023.176234
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0801 Artificial Intelligence and Image Processing, 1115 Pharmacology and Pharmaceutical Sciences, 1701 Psychology, 1702 Cognitive Sciences
dc.subject.classification	Behavioral Science & Comparative Psychology
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.classification	3109 Zoology
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.classification	5204 Cognitive and computational psychology
dc.subject.classification	5205 Social and personality psychology
dc.title	Harnessing the neuroprotective effect of oral administration of benfotiamine in MPTP induced Parkinson's disease in rats.
dc.type	Journal Article
utslib.location.activity	Netherlands
utslib.for	0801 Artificial Intelligence and Image Processing
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
utslib.for	1701 Psychology
utslib.for	1702 Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Public Health
utslib.copyright.status	closed_access	*
dc.date.updated	2023-12-07T12:23:47Z
pubs.publication-status	Published online

Abstract:

The study was performed to evaluate the neuroprotective effects of Benfotiamine (BFT) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) in rats. The rats were given daily doses of BFT (100mg/kg, 200mg/kg) through oral administration for 42 days. The rats were given a single bilateral dosage of MPTP (0.1 mg/nostril) intranasally once before the drug treatment to induce PD. On day 42, the animals were subjected to various behavioral paradigms. Post-treatment with BFT for 42 days significantly improved the motor and nonmotor fluctuations of MPTP. The results demonstrated that treatment with BFT ameliorated MPTP-induced disorders in behavior, body balance, and dopamine levels in the mid-brain. Among the post-treated groups, a high dose of BFT was the most effective treatment. Mean values are indicated in ±SEM, n = 5***(p < 0.001) when compared with the vehicle control, n = 5 ### (p < 0.001) when compared with the disease control; (p < 0.001) when compared with the BFT per se; (p < 0.001) when compared with the low dose of BFT; (p < 0.001) when compared with the high dose of BFT. Our finding suggests that BFT contributed to superior antioxidant, and anti-inflammatory and could be a novel therapeutic method for PD management. In conclusion, BFT could be a potential drug candidate for curbing and preventing PD.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/173769